全文获取类型
收费全文 | 15451篇 |
免费 | 1088篇 |
国内免费 | 378篇 |
专业分类
耳鼻咽喉 | 55篇 |
儿科学 | 207篇 |
妇产科学 | 166篇 |
基础医学 | 1720篇 |
口腔科学 | 140篇 |
临床医学 | 634篇 |
内科学 | 2271篇 |
皮肤病学 | 255篇 |
神经病学 | 863篇 |
特种医学 | 314篇 |
外国民族医学 | 1篇 |
外科学 | 1027篇 |
综合类 | 2067篇 |
预防医学 | 727篇 |
眼科学 | 160篇 |
药学 | 2400篇 |
中国医学 | 3079篇 |
肿瘤学 | 831篇 |
出版年
2024年 | 53篇 |
2023年 | 182篇 |
2022年 | 369篇 |
2021年 | 423篇 |
2020年 | 345篇 |
2019年 | 692篇 |
2018年 | 678篇 |
2017年 | 497篇 |
2016年 | 357篇 |
2015年 | 403篇 |
2014年 | 642篇 |
2013年 | 819篇 |
2012年 | 772篇 |
2011年 | 884篇 |
2010年 | 676篇 |
2009年 | 657篇 |
2008年 | 655篇 |
2007年 | 725篇 |
2006年 | 626篇 |
2005年 | 475篇 |
2004年 | 444篇 |
2003年 | 467篇 |
2002年 | 407篇 |
2001年 | 431篇 |
2000年 | 289篇 |
1999年 | 246篇 |
1998年 | 170篇 |
1997年 | 176篇 |
1996年 | 103篇 |
1995年 | 101篇 |
1994年 | 84篇 |
1993年 | 74篇 |
1992年 | 67篇 |
1991年 | 66篇 |
1990年 | 61篇 |
1989年 | 54篇 |
1987年 | 50篇 |
1985年 | 271篇 |
1984年 | 389篇 |
1983年 | 265篇 |
1982年 | 268篇 |
1981年 | 244篇 |
1980年 | 204篇 |
1979年 | 220篇 |
1978年 | 171篇 |
1977年 | 99篇 |
1976年 | 167篇 |
1975年 | 135篇 |
1974年 | 90篇 |
1973年 | 84篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
《Vaccine》2016,34(39):4724-4731
Human papillomavirus (HPV) infection is the most common sexually transmitted disease worldwide. HPVs are oncogenic small double-stranded DNA viruses that are the primary causal agent of cervical cancer and other types of cancers, including in the anus, oropharynx, vagina, vulva, and penis. Prophylactic vaccination against HPV is an attractive strategy for preventing cervical cancer and some other types of cancers. However, there are few safe and effective vaccines against HPV infections. Current first-generation commercial HPV vaccines are expensive to produce and deliver.The goal of this study was to develop an alternate potent HPV recombinant L1-based vaccines by producing HPV virus-like particles into a vaccine that is currently used worldwide. Live attenuated measles virus (MV) vaccines have a well-established safety and efficacy record, and recombinant MV (rMV) produced by reverse genetics may be useful for generating candidate HPV vaccines to meet the needs of the developing world.We studied in non-human primate rMV-vectored HPV vaccine in parallel with a classical alum adjuvant recombinant HPV16L1 and 18L1 protein vaccine produced in Pichia pastoris. A combined prime-boost approach using both vaccines was evaluated, as well as immune interference due to pre-existing immunity against the MV.The humoral immune response induced by the MV, Pichia-expressed vaccine, and their combination as priming and boosting approaches was found to elicit HPV16L1 and 18L1 specific total IgG and neutralizing antibody titres. Pre-existing antibodies against measles did not prevent the immune response against HPV16L1 and 18L1. 相似文献
3.
4.
5.
Michelle Linda Ferderbar Thomas E. Doyle Reza Samavi David Koff 《Journal l'Association canadienne des radiologistes》2019,70(2):119-124
Several regulatory bodies have agreed that low-dose radiation used in medical imaging is a weak carcinogen that follows a linear, non-threshold model of cancer risk. While avoiding radiation is the best course of action to mitigate risk, computed tomography (CT) scans are often critical for diagnosis. In addition to the as low as reasonably achievable principle, a more concrete method of dose reduction for common CT imaging exams is the use of a diagnostic reference level (DRL). This paper examines Canada's national DRL values from the recent CT survey and compares it to published provincial DRLs as well as the DRLs in the United Kingdom and the United States of America for the 3 most common CT exams: head, chest, and abdomen/pelvis. Canada compares well on the international scale, but it should consider using more electronic dose monitoring solutions to create a culture of dose optimization. 相似文献
6.
蛇床子水提取液抑瘤作用的实验研究 总被引:13,自引:0,他引:13
目的 :研究蛇床子水提取液的体内抗肿瘤作用。方法 :通过 S180 肉瘤移植建立荷瘤小鼠模型 ,给予不同剂量蛇床子水提取液后观察 S180 荷瘤小鼠肿瘤生长曲线、血清唾液酸 (SA)、瘤重及小鼠生存天数的变化。结果 :蛇床子水提取液能明显抑制肿瘤生长 ,降低荷瘤小鼠血清 SA水平 ,0 .0 6mg/(g· d) ,0 .1 1 mg/(g· d)、0 .2 1 mg/(g· d)剂量组平均瘤重低于肿瘤对照组 (P<0 .0 5 ) ,抑瘤率依次为 2 3 .2 %、2 9.1 %和 2 4 .8%,且能延长荷瘤小鼠生存天数 (P<0 .0 1 ) ,动物生命延长率依次为 :2 6 .9%、3 4 .8%和 2 6 .6 %。结论 :蛇床子水提取液具有较强的抗肿瘤效应 ,有很好的利用前景 ,值得对其进行深入研究。 相似文献
7.
二乙酰二脱水卫矛醇对小鼠白血病L1210细胞增殖的影响 总被引:5,自引:0,他引:5
目的 研究二乙酰二脱水卫矛醇 (1 ,2 :5 ,6 dianhydro 3 ,4 diacetylgalactitol,DADAG)的抗脑白血病作用及机制。方法 用小鼠脑内移植瘤模型、MTT法、DNA掺入法、流式细胞仪和Westernblot法 ,观察DADAG对小鼠脑内移植瘤和体外白血病L1 2 1 0 细胞的作用 ,并探讨作用机制。结果 DADAG对DBA/ 2小鼠脑内移植白血病L1 2 1 0 有明显的抑制作用 ;对体外白血病L1 2 1 0 细胞同样有很强的抗增殖作用 ,其IC50 值为 2 4 6mg·L- 1 。DADAG不可逆地抑制L1 2 1 0 细胞内DNA的生物合成。DADAG 2 4mg·L- 1 处理L1 2 1 0 细胞 6h后 ,细胞发生G2 /M周期阻滞 ,2 4h后达最高峰。细胞周期素B1 蛋白水平在DADAG处理 2 4h后开始下降 ,而磷酸化的细胞周期依赖性激酶CDK1在DADAG处理 6h后开始上调 ,并呈时间依赖性。结论 DADAG的抗脑白血病作用与其抑制白血病细胞的增殖密切相关 相似文献
8.
傣药芽拉勐龙(Cassia alata L.)是傣医药史籍中有记载且傣医临床中最常用的药材之一,它在泰国应用同样广泛多见,是已开发应用得较为成熟的药用植物,相关研究也较多。在西双版纳,民间傣医常在夏秋季节采收芽拉勐龙,认为这期间的芽拉勐龙叶才有更好的疗效,但尚未发现相关的理论依据支持这种说法,因此笔者在2008年7月到11月间,采集每个月份的芽拉勐龙叶进行其乙醇提取物的含量测定,以找到它的最佳采集使用期。通过其采收季节中有效成分含量的比较结果显示,有效成分最高的时间是11月份,故在采收芽拉勐龙时,应掌握时机,在11月份采收为佳。 相似文献
9.
Robert M. Levy Roman Saikovsky Evgeniya Shmidt Alexander Khokhlov Bruce P. Burnett 《Nutrition Research》2009
Flavocoxid (Limbrel), a proprietary mixture of flavonoid molecules (baicalin and catechin), was tested against a traditional nonsteroidal anti-inflammatory drug, naproxen, for the management of the signs and symptoms of moderate osteoarthritis (OA) in humans. Discomfort and global disease activity were used as the primary end points, and safety assessments were also taken for both treatments as a secondary endpoint. In this double-blind study, 103 subjects were randomly assigned to receive either flavocoxid [500 mg twice daily (BID)] or naproxen (500 mg BID) in a 1-month onset of action trial. Outcome measures included the short Western Ontario and McMaster University Osteoarthritis Index, subject Visual Analogue Scale for discomfort and global response, and investigator Visual Analogue Scale for global response and fecal occult blood. Both flavocoxid and naproxen showed significant reduction in the signs and symptoms of knee OA (P ≤ .001). There were no statistically detectable differences between the flavocoxid and naproxen groups with respect to any of the outcome variables. Similarly, there were no statistically detectable differences between the groups with respect to any adverse event, although there was a trend toward a higher incidence of edema and nonspecific musculoskeletal discomfort in the naproxen group. In this short-term pilot study, flavocoxid was as effective as naproxen in controlling the signs and symptoms of OA of the knee and would present a safe and effective option for those individuals on traditional nonsteroidal anti-inflammatory drugs or cyclooxygenase-2 inhibitors. A low incidence of adverse events was reported for both groups. 相似文献
10.
Marc Ziegler Alexandre Castro-Caldas Susanna Del Signore Olivier Rascol 《Movement disorders》2003,18(4):418-425
Piribedil is a non-ergot D2/D3 agonist with a significant antagonist action on alpha2A and alpha2C adrenergic receptor subtypes. This double-blind placebo-controlled study was undertaken to confirm the efficacy of 150 mg/day piribedil po in improving motor symptoms of idiopathic Parkinson's disease (PD) in nonfluctuating patients insufficiently controlled by a stable daily dose of levodopa (L-dopa). Efficacy was assessed using the Unified Parkinson's Disease Rating Scale (UPDRS) III score as primary criterion over 4 months. A second comparison was planned at 6 months, after possible adjustment of L-dopa. At 4 months, the rate of response, defined as a 30% decrease from baseline on UPDRS III score, was significantly greater with piribedil compared with placebo (56.4% vs. 37.7%; P = 0.040). At 6 months, the better efficacy of piribedil was maintained (61.8% of responders vs. 39.6% on placebo; P = 0.020). The difference between groups on UPDRS III change from baseline reached statistical significance only at 6 months: -10.0 points in the piribedil group vs. -6.7 points in the placebo group (P = 0.037). Secondary end-points were not significantly different. The most frequently reported adverse events were gastrointestinal symptoms (27 of 61 patients in the piribedil group vs. 13 of 54 patients in the placebo group). In conclusion, a 6-month oral administration of 150 mg/day piribedil in combination with L-dopa is well tolerated, except for minor gastrointestinal symptoms at the beginning of the treatment and significantly improves motor symptoms compared with placebo in PD nonfluctuating patients. 相似文献